- Home
- TPST vs RVPH Comparison
TPST vs RVPH Comparison
Compare TPST & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- RVPH
- Stock Information
- Founded
- TPST 2011
- RVPH 2006
- Country
- TPST United States
- RVPH United States
- Employees
- TPST N/A
- RVPH N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- RVPH Health Care
- Exchange
- TPST Nasdaq
- RVPH Nasdaq
- Market Cap
- TPST 33.0M
- RVPH 32.8M
- IPO Year
- TPST N/A
- RVPH N/A
- Fundamental
- Price
- TPST $7.44
- RVPH $0.38
- Analyst Decision
- TPST Hold
- RVPH Strong Buy
- Analyst Count
- TPST 3
- RVPH 5
- Target Price
- TPST $30.00
- RVPH $9.00
- AVG Volume (30 Days)
- TPST 234.4K
- RVPH 2.8M
- Earning Date
- TPST 08-07-2025
- RVPH 08-13-2025
- Dividend Yield
- TPST N/A
- RVPH N/A
- EPS Growth
- TPST N/A
- RVPH N/A
- EPS
- TPST N/A
- RVPH N/A
- Revenue
- TPST N/A
- RVPH N/A
- Revenue This Year
- TPST N/A
- RVPH N/A
- Revenue Next Year
- TPST N/A
- RVPH N/A
- P/E Ratio
- TPST N/A
- RVPH N/A
- Revenue Growth
- TPST N/A
- RVPH N/A
- 52 Week Low
- TPST $5.35
- RVPH $0.30
- 52 Week High
- TPST $30.03
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- TPST 56.13
- RVPH 31.86
- Support Level
- TPST $7.06
- RVPH $0.35
- Resistance Level
- TPST $7.18
- RVPH $0.83
- Average True Range (ATR)
- TPST 0.28
- RVPH 0.06
- MACD
- TPST 0.03
- RVPH -0.02
- Stochastic Oscillator
- TPST 93.18
- RVPH 14.45
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.